enVVeno Medical (NVNO) CTO surrenders 50,000 performance RSUs

Rhea-AI Filing Summary

enVVeno Medical Corp executive Hamed Alavi, the company’s Chief Technology Officer, reported a change in his equity holdings. A Form 4 filing shows that 50,000 restricted stock units were surrendered and cancelled at a price of $0. These units were originally issued on November 30, 2021 under the Amended and Restated 2016 Omnibus Incentive Plan and were subject to performance-based vesting conditions.

The filing explains that the specified performance milestones were not achieved, and therefore the unvested restricted stock units were voluntarily cancelled. Following this transaction, the number of derivative securities of this type beneficially owned by Alavi is reported as 0.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alavi Hamed

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	12/16/2025		J			50,000	(1)	11/30/2031	Common Stock	50,000	$0	0	D

Explanation of Responses:

1. The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.

	/s/ Hamed Alavi	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did enVVeno Medical Corp (NVNO) report in this Form 4?

The Form 4 reports that Chief Technology Officer Hamed Alavi voluntarily surrendered and cancelled 50,000 restricted stock units at a price of $0.

Why were 50,000 enVVeno Medical (NVNO) restricted stock units cancelled?

The filing states that the performance milestones tied to the restricted stock units were not achieved, so the unvested units were surrendered and cancelled.

When were the cancelled NVNO restricted stock units originally granted?

The restricted stock units were issued on November 30, 2021 under enVVeno Medical’s Amended and Restated 2016 Omnibus Incentive Plan.

What type of derivative security was involved in the NVNO Form 4 filing?

The derivative security was restricted stock units, each representing the right to receive one share of enVVeno Medical Corp common stock upon vesting.

How many derivative securities does the enVVeno Medical CTO hold after this transaction?

Following the reported transaction, the number of these derivative securities beneficially owned by the CTO is reported as 0.

What was the exercise or conversion price for the cancelled NVNO restricted stock units?

The Form 4 lists the conversion or exercise price of the restricted stock units as $0.